Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
暂无分享,去创建一个
Seth M Steinberg | S. Steinberg | S. Rosenberg | J. Yang | D. White | N. Restifo | M. Dudley | C. Laurencot | Debbie-Ann N. Nathan | R. Sherry | M. Hughes | U. Kammula | G. Phan | J. Wunderlich | R. Somerville | Colin Gross | Nicholas P Restifo | Steven A Rosenberg | Nicholas P. Schaub | Nicholas P Schaub | James C Yang | John R Wunderlich | Mark E Dudley | Udai S Kammula | Richard M Sherry | Marybeth S Hughes | Y. Hong | Colin A Gross | Robert P T Somerville | Young Hong | Shannon F Rosati | Donald E White | Debbie Nathan | Giao Q Phan | Carolyn M Laurencot | Shannon F. Rosati | Nicholas Schaub
[1] S. Rosenberg,et al. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. , 2009, Journal of immunotherapy.
[2] E. Shevach,et al. Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells1 , 2005, The Journal of Immunology.
[3] S. Steinberg,et al. Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL , 2010, Journal of immunotherapy.
[4] M. Brenner. Will T-cell therapy for cancer ever be a standard of care? , 2012, Cancer Gene Therapy.
[5] Jeffrey E. Lee,et al. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.
[6] S. Rosenberg,et al. CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma , 2010, Clinical Cancer Research.
[7] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[8] E. Shevach,et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.
[9] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[10] M. Dudley,et al. Bioreactors get personal , 2012, Oncoimmunology.
[11] Steven A. Rosenberg,et al. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know , 2011, Nature Reviews Clinical Oncology.
[12] B. Shalmon,et al. Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy , 2011, Journal of immunotherapy.
[13] G. Wagenius,et al. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy , 2012, Cancer Immunology, Immunotherapy.
[14] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Marianna Sabatino,et al. Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment , 2012, Journal of immunotherapy.
[16] S. Steinberg,et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.
[17] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[18] S. Rosenberg,et al. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor , 2012, Journal of Translational Medicine.
[19] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[20] M. Donia,et al. Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour‐Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution , 2012, Scandinavian journal of immunology.
[21] S. Rosenberg,et al. Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy , 2010, Journal of immunotherapy.
[22] Steven A. Rosenberg,et al. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients , 2003, Journal of immunotherapy.
[23] S. Rosenberg,et al. Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy , 2008, Journal of immunotherapy.
[24] Helen E Heslop,et al. Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex) , 2010, Journal of immunotherapy.
[25] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] V. Sondak,et al. New Challenges in Endpoints for Drug Development in Advanced Melanoma , 2011, Clinical Cancer Research.
[27] S. Rosenberg,et al. Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes , 2012, Journal of immunotherapy.
[28] S. Riddell,et al. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. , 1990, Journal of immunological methods.
[29] V. Sondak,et al. Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.